CRISPR Shares Tumble 2.47% as $280M Volume Surge Propels It to 460th Market Activity Rank Amid Pipeline and Regulatory Hurdles

On October 10, 2025, CRISPR Therapeutics (CRSP) closed at a 2.47% decline, with a trading volume of $280 million—a 37.45% increase from the previous day—ranking 460th in market activity. The biotech firm's shares faced pressure amid mixed signals from its therapeutic pipeline updates and regulatory uncertainties. Analysts noted that while recent data from preclinical trials showed incremental progress in gene-editing precision, the lack of concrete timelines for Phase III trials dampened investor optimism.

Market participants highlighted the stock's sensitivity to macroeconomic factors, as broader biotech indices underperformed due to rising borrowing costs. CRISPR's volume spike reflected heightened short-term speculation, though institutional holdings remained largely stable. A key catalyst for near-term volatility could emerge from its planned data releases in early 2026, which may clarify the commercial viability of its lead candidate for sickle cell disease.

To deliver an accurate back-test, I need to clarify a few details: Universe definition, trade execution assumptions, and benchmark parameters. Once these criteria are established, the analysis can proceed with precise data alignment to historical market conditions.